| Public | NASDAQ:ILMN |
| Date | 4/00 |
| Raised | |
| Post IPO Valuation |
| Website | illumina.com |
| Phone | 1-800-809-4566 |
| Employees |
| Verinata Health, 1/13 | |
| Helixis, 4/10 |
| GenoLogics | 2/12 |
| Oxford Nanopore Technologies | 4/10 |
| Genizon BioSciences | 3/06 |
At Illumina, their goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
